Deals
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The company offered 12 million shares at $18 per share and raised $216 million, 72% more than originally expected.
Shares of Forty Seven Inc. were up in premarket trading on rumors that Gilead Sciences has approached the company about a potential partnership or acquisition.
With the acquisition of San Diego-based PvP Biologics and a recent deal with COUR Pharmaceuticals, Takeda Pharmaceutical is looking to become a world leader in the treatment of celiac disease and other gastrointestinal disorders.
Three years after Takeda and San Diego-based PvP Biologics inked a $35 million deal to develop a novel treatment for celiac disease, the Japanese pharma company has exercised its option to acquire the company for $330 million.
Mallinckrodt Files Chapter 11 for its Generics Business as it Reaches $1.6 Billion Opioid Settlement
In addition to the settlement and bankruptcy, Mallinckrodt entered into a debt refinancing agreement, including an $800 million loan that will be used to repay some outstanding debt and acquire some outstanding stocks.
4basebio AG announces the allotment ratio and the final number of shares for the announced share buyback program.
The merged company will focus on advancing Forte’s clinical program in inflammatory skin diseases, including atopic dermatitis.
Montis Biosciences launched with €8,4 million seed financing and a novel approach to immune-oncology
Montis Biosciences announces its launch with €8,4 million in seed financing from an international investor syndicate to investigate interactions between perivascular macrophages and tumor vasculature.
“The good performance we saw in the third quarter has continued to further improve.
A group of unions and consumer organizations have banded together in opposition to the $63 billion merger citing concerns that it will create a monopoly and harm competition.